HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study

NCT ID: NCT05167071

Last Updated: 2025-04-27

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 53 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-12-28
• Study Completion Date: 2026-06-30

Brief Summary

To select RP2D/MTD of HBM4003 in combination with Toripalimab in dose confirmation part(Part 1) and use the RP2D in dose expansion part (Part 2) to evaluate the safety, tolerability, PK/PD and preliminary efficacy of in patients with advanced NEN and other solid tumors

Detailed Description

Subjects will be treated with HBM4003 in combination with Toripalimab for up to 2 years or until confirmed disease progression, unacceptable tolerability or treatment discontinuation through withdrawal of consent occurs, whichever happens first.

This trial consists of:

• A screening period: 28 days
• A treatment period: no longer than 2 years (Part 1 dose escalation study or Part 2 dose expansion)
• A post-treatment follow-up period, including 28 days and 84 days after the last dose of study drug;
• Survival follow-up.

Conditions

Solid Tumors; Neuroendocrine Tumors; CRC

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

HBM4003(dose 1) and Toripalimab

Arm A: HBM4003(dose 1) combined with Toripalimab in patients with advanced NEN

Group Type: EXPERIMENTAL

HBM4003

Intervention Type: DRUG

Subjects will be treated with HBM4003 on Day 1 during each 21-day cycle.

Toripalimab

Intervention Type: DRUG

Subjects will be treated with Toripalimab on Day 1 during each 21-day cycle.

HBM4003(dose 2) and Toripalimab

Arm B: HBM4003(dose 2) combined with Toripalimab in patients with advanced NEN

Group Type: EXPERIMENTAL

HBM4003

Intervention Type: DRUG

Subjects will be treated with HBM4003 on Day 1 during each 21-day cycle.

Toripalimab

Intervention Type: DRUG

Subjects will be treated with Toripalimab on Day 1 during each 21-day cycle.

HBM4003 and Tislelizumab

Arm F: HBM4003(dose 1) combined with Tislelizumab in patients with advanced CRC

Group Type: EXPERIMENTAL

HBM4003

Intervention Type: DRUG

Subjects will be treated with HBM4003 on Day 1 during each 21-day cycle.

Tislelizumab

Intervention Type: DRUG

Subjects will be treated with Tislelizumab on Day 1 during each 21-day cycle.

Interventions

HBM4003

Subjects will be treated with HBM4003 on Day 1 during each 21-day cycle.

Intervention Type: DRUG

Toripalimab

Subjects will be treated with Toripalimab on Day 1 during each 21-day cycle.

Intervention Type: DRUG

Tislelizumab

Subjects will be treated with Tislelizumab on Day 1 during each 21-day cycle.

Intervention Type: DRUG

Other Intervention Names

Porustobart

Eligibility Criteria

Inclusion Criteria

1. Males or females aged ≥ 18 years at the time of signing the informed consent form. For Part 1 of this study, the subjects should be ≤ 75 years of age.

2. Patients for Part 1: patients histopathologically diagnosed with advanced or recurrent solid tumors.

3. For arm A and B of Part 2 in the study, Patients with non- functional metastatic neuroendocrine tumor confirmed by histopathology.

4. For arm F of Part 2 in the study, Patients with metastatic colorectal adenocarcinoma diagnosed by histopathology.

5. Patients must be able to provide archived tumor tissues after latest treatment or fresh tumor tissues and relevant pathology report.

6. Patients whose estimated survival time is more than 3 months.

7. Patients with at least one measurable lesion at baseline according to RECIST (Version 1.1). The lesion had not previously received surgery, radiotherapy and/or local treatment.

8. Patients with Eastern Cooperative Oncology Group(ECOG) performance status score ≤1.

9. Every woman or man with potential fertility needs to use an effective contraceptive method during the study, up to within 3 months after last drug administration.

10. Willing and able to comply with study-specified visits schedule, treatment plan, laboratory examination and other study procedures.

Exclusion Criteria

1. Patients who are simultaneously participating in another clinical study.

2. Patients with a history of severe allergic diseases, a history of severe drug allergies, and known or suspected allergy to macromolecular protein preparations or HBM4003 or Toripalimab or Tislelizumab or its excipients.

3. Previous and concomitant drugs or treatments to be excluded like:

• Anti-CTLA4 drug;
• For part 1, anti-PD1 anti-PDL1 or anti-PDL2 treatment was received within 8 weeks prior to the start of the study;
• For part 2, patients received anti-PD1, anti-PDL1 or anti-PDL2 treatment during the relapse or metastasis stage, and the time from the last treatment is short than 12 months before the first dose;
• Received other antitumor treatment (including chemotherapy, radiation, targeted therapy, or biotherapy), antitumor vaccine, chinese herbal medicine or proprietary medicine with anti-tumor effect, Immunosuppressant or glucocorticoid, Transfusion of PLT or RBC prior to initiation of study treatment;
• live attenuated vaccine was received before study administration or planned during the study period.

4. Insufficient recovery from previous treatments.

5. Diseases that may affect the efficacy and safety of the investigational product, including but not limited to active infection, active autoimmune disease or autoimmune disease, primary immunodeficiency disease, any clinically significant cardiovascular disease, severe pulmonary insufficiency, organ transplantation, etc.

6. A history of other malignant diseases within 5 years before the first dose.

7. Symptomatic, active, or urgent treatment-requiring central nervous system (CNS) metastasis with imaging evidence (based on CT or MRI assessment).

8. Subjects with pleural effusion, pericardial effusion, or ascites that could not be stabilized by repeated drainage or other methods were determined by investigator.

9. Patients who the investigator believes may have other factors that will affect the efficacy or safety evaluation of this study (e.g., mental disorders, alcoholism, drug use, etc.).

10. Women who are pregnant or breastfeeding, or who plan to become pregnant during the study period and within 3 months after the last administration of the investigational product.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Harbour BioMed (Guangzhou) Co. Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Lin Shen, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Peking University Cancer Hospital & Institute

Locations

Beijing Cancer Hospital

Beijing, , China

Countries

China

References

Zhang P, Chen K, Yang J, Song L, Zheng F, Luo R, He Y, Li F, Yang D, Cao N, Tao X, Shen L, Lu M. Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II study. EClinicalMedicine. 2025 Jun 3;84:103249. doi: 10.1016/j.eclinm.2025.103249. eCollection 2025 Jun.

Reference Type: DERIVED

PMID: 40521168 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Other Identifiers

4003.6

Identifier Type: -

Identifier Source: org_study_id